Jiangzhong Pharmaceutical (600750): Under short-term pressure from a high revenue base, profit growth in the main business exceeded expectations
Jiangzhong Pharmaceutical (600750): Profit growth under the 2024Q1 high base, “improving quality, efficiency, and valuing return” actions are imminent
Jiangzhong Pharmaceutical (600750): Under high base, 24Q1 performance is under pressure in the short term, OTC business is growing steadily
Jiangzhong Pharmaceutical (600750): Gastrointestinal category leader's “high dividend+state-owned enterprise” value reshaping
Jiangzhong Pharmaceutical (600750): Improving Quality and Efficiency, High Growth, Brand Building Results Remarkable
Jiangzhong Pharmaceutical (600750): Performance is in line with expectations, high dividends, high quality assets
Jiangzhong Pharmaceutical (600750): Steady performance growth, “high dividend+state-owned enterprise” investment value highlighted
Jiangzhong Pharmaceutical (600750): Profitability continues to improve with the concerted efforts of the three business sectors
Jiangzhong Pharmaceutical (600750): The three major sectors in Q3 remained flat year on year, and high dividends highlight long-term value
Jiangzhong Pharmaceutical (600750): Q3 quarterly revenue under short-term pressure, cost optimization driving high profit growth
Jiangzhong Pharmaceutical (600750): Focus on three key business layouts and achieve steady growth in H1 core categories
Jiangzhong Pharmaceutical (600750): The company's performance is growing steadily, and gross margin is steadily increasing
Jiangzhong Pharmaceutical (600750): Semi-annual performance growth is steady and core products continue to be released
Jiangzhong Pharmaceutical (600750): Endogenous cultivation extends the second growth curve, China Resources empowers and increases ROE
Jiangzhong Pharmaceutical (600750) Company Dynamic Review: “Endogenous+Outreach” Dual Wheel Drive Performance Growth Meets Expectations
Jiangzhong Pharmaceutical (600750) Company Dynamic Review: Three Sectors Go Hand in Hand, Performance Growth Exceeds Expectations
Jiangzhong Pharmaceutical (600750): Interim performance growth rate is impressive, net profit growth exceeds expectations
Jiangzhong Pharmaceutical (600750) Company Dynamic Review: Integrating Lossless Health Liquor Business Focusing on OTC+ Big Health
Jiangzhong Pharmaceutical (600750): Strengthening the gastrointestinal moat and rich product matrix to create a new growth pole
Dynamic comment of Jiang Zhong Pharmaceutical (600750) Co., Ltd.: OTC+ Great Health two-wheel drive business recovery situation is good
No Data